Encyclopedia entry
Kisspeptin-10
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-04
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Kisspeptin-10
Kisspeptin-10 is a 10-amino-acid fragment of the KISS1 gene product, an endogenous neuropeptide that regulates pulsatile GnRH secretion from the hypothalamus. It is the subject of active legitimate academic research at Imperial College London (the Dhillo group) examining its physiological role in reproductive medicine. It is not a licensed medicine in any jurisdiction. UK availability outside academic research is via research-peptide retailers under research-use-only framing.
Mechanism of action
How Kisspeptin-10 works
Kisspeptin-10 acts as an agonist at the KISS1 receptor (formerly GPR54), a G-protein-coupled receptor expressed on GnRH neurons in the hypothalamus. Activation of KISS1R drives pulsatile release of GnRH, which in turn stimulates LH and FSH secretion from the anterior pituitary. The kisspeptin system is required for normal puberty onset and reproductive cyclicity across species. Loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism in humans, the original evidence for the system's central role in the HPG axis.
Source: Dhillo WS et al. peer-reviewed publications, Imperial College London
What the academic literature shows
Kisspeptin-10 has a higher methodological quality of evidence than most research peptides in this encyclopedia, owing to involvement of UK NHS-affiliated institutions. The Dhillo group at Imperial College London has published over 50 peer-reviewed papers on kisspeptin physiology in humans since the mid-2000s. The compound is used as a research tool to probe HPG-axis function, not as a candidate therapeutic for a single licensed indication.
- · Kisspeptin and its receptor KISS1R (formerly GPR54) were identified as essential regulators of the hypothalamic-pituitary-gonadal axis following discovery that GPR54 loss-of-function mutations cause hypogonadotropic hypogonadism.
- · The Dhillo group at Imperial College London has published over 50 peer-reviewed papers on kisspeptin in humans, including studies of GnRH pulse modulation in healthy volunteers and specific patient populations.
- · Animal studies across multiple species confirm that kisspeptin signalling is required for normal puberty onset and reproductive cyclicity.
- · Human studies have examined Kisspeptin-10 as a research tool to probe GnRH pulse generation in physiological and pathophysiological conditions.
- · No randomised controlled trial has led to a regulatory submission for a kisspeptin-based licensed medicine in any jurisdiction as of this editorial date.
- · Academic research conducted under ethics approval is not the same as a licensed pharmaceutical product, even when the academic data is methodologically sound.
Evidence quality assessment: the academic literature is of higher methodological quality than many research peptides because of NHS-affiliated institutional involvement. Nonetheless, the compound remains unlicensed and the human studies are mechanistic research tools, not clinical efficacy trials for an approved indication.
UK regulatory status
Kisspeptin-10 sits outside the Misuse of Drugs Act 1971 and outside the Psychoactive Substances Act 2016. It holds no UK marketing authorisation as a medicine. Academic research use at Imperial College London and other UK institutions is conducted under appropriate MHRA clinical trial authorisations and ethics approvals. UK retailers can sell it lawfully only by labelling it for "research use only" and avoiding any therapeutic claim.
- · Not a controlled drug under the Misuse of Drugs Act 1971.
- · Not scheduled under the Psychoactive Substances Act 2016.
- · No MHRA marketing authorisation as a medicine in the UK.
- · Academic research use at institutions such as Imperial College London is conducted under appropriate MHRA clinical trial authorisations (CTAs) and ethics approvals. This is distinct from commercial sale as a research chemical.
- · Sold legally as a research chemical by UK retailers when marketed without therapeutic claims.
- · Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
- · The legitimate academic research context does not change the regulatory status of commercially sold Kisspeptin-10: it remains an unlicensed product outside of authorised clinical trials.
Risks and unknowns
What the literature does not yet show about Kisspeptin-10
Known concerns
- No published Phase III RCT data on safety profile or long-term tolerability outside the Imperial College mechanistic-study programme.
- The compound used in academic research is supplied through pharmaceutical-grade channels separate from the retail research-peptide market.
- Purity of UK research-peptide supply varies between retailers. CoA gating and HPLC analysis differ.
- The retail research-peptide market is not the supply chain used by NHS-affiliated academic researchers.
Open questions in the literature
- Pharmacokinetics and dynamics of repeated long-term administration in non-research populations are not characterised.
- Whether sustained HPG-axis modulation is benign in the general population is not established.
- Effects of co-administration with hormonal contraceptives or hormone replacement therapy are not characterised.
- Whether retail-tier Kisspeptin-10 matches the purity profile of pharmaceutical-grade research material is variable and not publicly verifiable.
Regulatory note
Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Academic research use at Imperial College London is conducted under appropriate MHRA CTAs and ethics approvals. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Where to learn more
- · PubMed search: Kisspeptin-10 returns substantial peer-reviewed literature from animal and human studies.
- · PubMed: Dhillo WS et al. (Imperial College London) for the UK academic clinical research programme.
- · ClinicalTrials.gov: Kisspeptin for registered UK and international academic trials.
- · UK retailer purity comparison: research peptides UK retailers.
Frequently asked questions
Is Kisspeptin-10 legal in the UK?
What does the human evidence show for Kisspeptin-10?
What is the regulatory status of Kisspeptin-10 in the UK?
What forms is Kisspeptin-10 available in?
Where can I learn more about Kisspeptin-10?
Where to buy Kisspeptin-10 in the UK
Compare UK research-peptide retailers stocking Kisspeptin-10, with current prices and CoA status. Research use only, not for human or animal consumption.
Compare Kisspeptin-10 pricesClinical evidence record
Read the clinical evidence record for Kisspeptin-10
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
Popular on PeptideClear
Ready to buy
Buy Kisspeptin-10 in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.